Navigation Links
Study Casts Doubt on Vaccine-Autism Link
Date:1/7/2008

Research adds to growing body of evidence thats finds no connection between the two

MONDAY, Jan. 7 (HealthDay News) -- Adding to a growing body of evidence that rejects the idea that immunizations boost autism rates, a new study finds no proof that incidences of the disorder dropped after makers of most childhood vaccines stopped using a mercury-based preservative in their products.

Researchers found that autism rates in California continued to rise over the past several years, even though the preservative -- known as thimerosal -- had vanished from almost all vaccines by 2001.

The study makes clear that "thimerosal cannot be the major cause of autism in California," said its lead author, Dr. Robert Schechter, medical officer with the Immunization Branch of the California Department of Public Health.

Another expert called the study limited and said it did not prove that vaccines have no connection to autism.

Still, the new research "adds to the body of existing evidence in which there is no causal connection that demonstrates thimerosal is a primary cause" of autism, said Andy Shih, vice president of scientific affairs for Autism Speaks, an advocacy organization.

Thimerosal, a preservative once used in contact lens solutions, was frequently a component of childhood vaccines until around 2000. Today, it's still used in flu vaccines recommended for infants, but researchers think children are still exposed to much less thimerosal than in the past.

In recent years, some parents have blamed their children's autism on the preservative, which is derived from mercury; others have accused the parents of creating public panic and threatening the health of children by casting a bad light on routine immunizations.

One government study released in 2007 claimed that thimerosal exposure in the first seven months of life didn't appear to affect the brain function of children aged 7 to 10, although there was some evidence -- perhaps the result of chance -- that connected thimerosal to later development of physical tics. Even earlier, an Institute of Medicine report released in 2004 found no evidence supporting a link between thimerosal and autism.

In the new study, published in the January issue of the Archives of General Psychiatry, researchers from the California Department of Public Health examined statistics about children in the state from 1995 through March 2007.

The prevalence of autism among kids aged 3 to 12 grew each year, the researchers discovered after looking at numbers compiled by a state agency that provides services to children with the disorder.

For example, the prevalence among kids born in 1993 was three in 10,000 when they were checked in 1996, compared to 13 per 10,000 among those born in 2003 and checked in 2006.

The highest rate -- 4.5 cases per 1,000 births -- came among 6-year-olds in 2006 who were born in 2000.

The study authors pointed out that autism rates among kids aged 3 to 5 continued to grow for each birth year after 1999, even though thimerosal use dropped.

Shih said the study methods are "robust," adding that the authors appeared to address limitations of earlier studies. However, he said, the research "doesn't address the possibility that there might be a subpopulation who might be particularly vulnerable to a vaccine with thimerosal."

If just 1 percent to 2 percent of children were especially sensitive to the effect of thimerosal, the study wouldn't be able to pick it up, he said.

Schechter agreed, saying it was true that the research didn't address whether thimerosal might cause problems in a small number of cases.

As for a possible link between vaccines and autism, Shih said, "the jury is still out," especially considering that children are exposed to a large number of vaccines before age 2.

And he added, "Some people in the community feel that they might lead to immune problems that could either exacerbate or lead to autism. All this is purely hypothetical, but this is an area where we need to continue to do more research."

More information

To learn more about vaccines, visit the U.S. Centers for Disease Control and Prevention.



SOURCES: Robert Schechter, M.D., medical officer, Immunization Branch, California Department of Public Health, Richmond; Andy Shih, Ph.D., vice president, scientific affairs, Autism Speaks, New York City; January 2008, Archives of General Psychiatry


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Columbia Center for Childrens Environmental Health receives NIEHS grant to study asthma
2. Risk factors for Parkinsons disease under study
3. Patient-Centric Healthcare Study Reveals Key Insights for Pharmaceutical Marketers
4. Circumcision doesnt reduce sexual satisfaction and performance, says study of 4,500 men
5. Pollution shrinks fetus size: Brisbane study finds
6. Researchers use neuroimaging to study ESP
7. Study finds most TV prescription drug ads minimize risk information
8. UGA researchers receive $9 million in grants to study barriers to effective addiction treatment
9. Study Spotlights a Natural Infection Fighter
10. Carnegie Mellon study identifies where thoughts of familiar objects occur inside the human brain
11. American College of Physicians receives grant to study cost of patient-centered medical home
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Casts Doubt on Vaccine-Autism Link
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , ... Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day ... at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology: